A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1040-1048

  Takata, Miyako ^a   Chikumi, Hiroki ^a,b   Matsunami, Keiji ^a   Kodani, Masahiro ^a   Sakamoto, Tomohiro ^a   Hashimoto, Kazuhiro ^c   Nakamoto, Masaki ^a,b   Okada, Kensaku ^a   Kitaura, Tsuyoshi ^a   Matsumoto, Shingo ^d   Kurai, Jun ^a   Yamasaki, Akira ^a   Igishi, Tadashi ^a   Burioka, Naoto ^a   Shimizu, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

^c Kyowa Pharmaceutical Industry Co   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

EGFR mutations; Epidermal growth factor receptor; Non small cell lung cancer; Ultrarapid PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ARTICLE; BRONCHOSCOPY; CANCER PATIENT; CYTOLOGY; EGFR GENE; FEASIBILITY STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG CANCER CELL LINE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; NON SMALL CELL LUNG CANCER; POINT OF CARE TESTING; RAPID TEST; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; THERMOREGULATION; TURNAROUND TIME; WILD TYPE; ADULT; CASE REPORT; FEMALE; GENETICS; HOSPITAL INFORMATION SYSTEM; LUNG TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; POINT-OF-CARE SYSTEMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84921689213     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3716     Document Type: Article

References (31)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781, 2010.
2. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009.
3. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
4. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010.
5. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010.
6. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
7. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012.
8. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011.
9. Han JY, Park K, Kim SW, et al: First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122-1128, 2012.
10. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
11. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from-never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311, 2004.
12. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005.
13. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmallcell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501, 2005.
14. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919-8923, 2004.
15. Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13:4954-4955, 2007.
16. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817-1824, 2007.
17. Hall JG, Eis PS, Law SM, et al: Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci USA 97:8272-8277, 2000.
18. Naoki K, Soejima K, Okamoto H, et al: The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. Int J Clin Oncol 16:335-344, 2011.
19. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276-7282, 2005.
20. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 8:335-341, 2006.
21. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915-3921, 2006.
22. Takata M, Chikumi H, Miyake N, et al: Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biol Ther 13:369-378, 2012.
23. Fujimoto T, Konagaya M, Enomoto M, et al: Novel high-speed real-time PCR method (Hyper-PCR): results from its application to adenovirus diagnosis. Jpn J Infect Dis 63:31-35, 2010.
24. ®Green real-time PCR for detection and discrimination of Listeria spp- and Listeria monocytogenes. Appl Microbiol Biotechnol 97:4021-4037, 2013.
25. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169-193, 2000.
26. Newton CR, Graham A, Heptinstall LE, et al: Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516, 1989.
27. Newton CR, Kalsheker N, Graham A, et al: Diagnosis of a1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products. Nucleic Acids Res 16:8233-8243, 1988.
28. Ellison G, Zhu G, Moulis A, Dearden S, Speake G and McCormack R: EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66:79-89, 2013.
29. Goto K, Satouchi M, Ishii G, et al: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 23:2914-2919, 2012.
30. Kim YH, Yang I, Bae YS and Park SR: Performance evaluation of thermal cyclers for PCR in a rapid cycling condition. Biotechniques 44:495-496, 498, 500 passim, 2008.
31. Nitsche A: Oligonucleotide design for in-house real-time PCR applications in microbiology. In: Real-.ime PCR in Microbiology. Mackay IM (ed). Caister Academic Press, Norfolk, pp41-69, 2007.